Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,500,000 shares, a decline of 6.0% from the October 15th total of 2,660,000 shares. Approximately 6.9% of the company’s stock are short sold. Based on an average daily trading volume, of 437,200 shares, the short-interest ratio is presently 5.7 days.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 60,743 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the transaction, the chief financial officer now owns 101,360 shares of the company’s stock, valued at approximately $5,245,380. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 28,816 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $53.13, for a total transaction of $1,530,994.08. Following the sale, the executive vice president now owns 69,669 shares of the company’s stock, valued at approximately $3,701,513.97. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO William J. Peters sold 60,743 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the sale, the chief financial officer now directly owns 101,360 shares in the company, valued at approximately $5,245,380. The disclosure for this sale can be found here. Insiders have sold a total of 95,559 shares of company stock valued at $4,982,484 in the last 90 days. Insiders own 28.40% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several large investors have recently made changes to their positions in AMPH. West Tower Group LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $39,000. Point72 Middle East FZE acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $50,000. Ronald Blue Trust Inc. increased its holdings in Amphastar Pharmaceuticals by 821.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after acquiring an additional 1,068 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after acquiring an additional 628 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth $59,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $55.85 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.11 and a quick ratio of 1.68. The firm has a fifty day moving average price of $47.41 and a 200 day moving average price of $50.47. Amphastar Pharmaceuticals has a 1 year low of $27.58 and a 1 year high of $67.66. The stock has a market cap of $2.73 billion, a P/E ratio of 21.82 and a beta of 0.87.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th. Jefferies Financial Group started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They set a “buy” rating and a $70.00 price objective for the company. Bank of America started coverage on shares of Amphastar Pharmaceuticals in a research note on Friday. They set a “neutral” rating and a $63.00 price objective for the company. Finally, StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 13th.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).